WO2020237836A1 - Preparation method for 4-idarubicin hydrochloride - Google Patents
Preparation method for 4-idarubicin hydrochloride Download PDFInfo
- Publication number
- WO2020237836A1 WO2020237836A1 PCT/CN2019/100198 CN2019100198W WO2020237836A1 WO 2020237836 A1 WO2020237836 A1 WO 2020237836A1 CN 2019100198 W CN2019100198 W CN 2019100198W WO 2020237836 A1 WO2020237836 A1 WO 2020237836A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- compound
- reaction
- molecular sieve
- batches
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Definitions
- the invention relates to the field of medicinal chemistry, in particular to a preparation method of 4-demethoxydaunorubicin hydrochloride.
- Anthracycline compounds are a class of substances widely used in the treatment of hematological malignancies and solid tumors, among which (7S,9S)-9-acetyl-7,8,9,10-tetrahydro-6,7,9, 11-tetrahydroxy-7-O-(2,3,6-tideoxy-3-amino- ⁇ -L-lyxo-hex-pyranose)-5,12-tetraphenyl hydrochloride, namely 4 -Demethoxydaunorubicin is a first-line drug for the treatment of relapsed and refractory adult acute myeloid leukemia (AML). It was developed and produced by Pharmacia Pretron and was approved by the FDA on September 27, 1990. Approved by CFDA in 2004 for listing. Compared with daunorubicin hydrochloride, 4-demethoxydaunorubicin has the advantages of less side effects, better curative effect, and lower drug resistance.
- the present invention aims to provide an improved (7S,9S)-9-acetyl-7,8,9,10-tetrahydro-6,7,9,11-tetrahydroxy-7-O suitable for scale-up production -(2,3,6-Tideoxy-3-amino- ⁇ -L-lyxo-hex-pyranose)-5,12-Phenyltetraphenyl hydrochloride synthesis method.
- the present invention provides a method for preparing a compound of formula C, the route is as follows:
- Compound B is reacted in the presence of anhydrous MgX 2 , YI and tetrabutylammonium halide to obtain compound C, wherein R 1 is selected from C1-C3 alkyl, X is halogen, and Y is alkali metal.
- the compound B: MgX 2 : YI: tetrabutylammonium halide 1:1 ⁇ 3:0.5 ⁇ 2:0.1 ⁇ 2 is charged in a molar ratio for reaction; preferably, it is in molar ratio
- X is selected from Cl, Br, or I; preferably Cl.
- Y is selected from Na or K; preferably K.
- the tetrabutylammonium halide is selected from one or a mixture of two or more of tetrabutylammonium chloride, tetrabutylammonium bromide or tetrabutylammonium iodide; preferably tetrabutylammonium iodide Ammonium.
- R 1 is methyl, ethyl, n-propyl or isopropyl; preferably methyl.
- the reaction solvent is tetrahydrofuran, dioxane or ethylene glycol dimethyl ether; preferably tetrahydrofuran.
- the above reaction temperature is 35-75°C; preferably 50-75°C; more preferably 50-60°C.
- the reaction time of the above reaction is 6 to 48 hours; preferably 10 to 36 hours, more preferably 12 to 24 hours.
- the above reaction process is carried out under water-controlled conditions; preferably, the water content of the reaction system is controlled within 3%; more preferably, the water content of the reaction system is controlled within 1%.
- nitrogen gas and/or molecular sieves are added to control moisture.
- the molecular screen is selected from or Molecular sieve; preferably Molecular sieve.
- the amount of molecular sieve added is 0.2 to 1 times that of Compound B by mass; preferably 0.3 to 0.8 times; more preferably 0.4 to 0.6 times; most preferably 0.5 times.
- the MgX 2 , YI and tetrabutylammonium halide are added to the reaction vessel by batch feeding.
- the solvent, compound B, and optional molecular sieve are added to the reaction vessel in the first batch of the above reaction; the second to the last batch is put into the pre-packed mixture of MgX 2 , YI and tetrabutylammonium halide
- the batches are fed in batches of 3-10 batches; more preferably, the batches are fed in 4-8 batches; more preferably, the batches are fed in 4-7 batches; most preferably, the batches are fed in 6 batches.
- the present invention provides a method for preparing compound C, the route is as follows:
- the reaction is carried out in the amount of feeding; in terms of mass ratio, the molecular sieve is 0.5 times that of compound B; the reaction temperature is 50-60°C; the reaction time is 11-15h; the reaction is carried out by batch feeding.
- the present invention provides a method for preparing compound D according to the following reaction route:
- the present invention provides a preparation method of compound E, which is carried out according to the following reaction route:
- the present invention provides a method for preparing compound F, which is carried out according to the following reaction route:
- the present invention provides a method for preparing compound B, wherein R 1 is a methyl group, and proceed according to the following reaction route:
- the new preparation method provided by the present invention can reduce the amount of salt used in the reaction system, reduce the impact of reduced yield due to reaction amplification, and inhibit the increase of impurity I and impurity II during the reaction process, and has great advantages in production practice .
- C1-C3 alkyl includes C1 alkyl, C2 alkyl, and C3 alkyl. Examples include but are not limited to methyl, ethyl, n-propyl, and isopropyl.
- TBAI refers to tetrabutylammonium iodide.
- K refers to potassium
- I means iodine.
- Me refers to methyl
- Compound C refers to a compound with a molecular structure of Formula C, rather than elemental carbon.
- Analytical method According to high performance liquid chromatography (Chinese Pharmacopoeia 2015 Edition Four General Rules 0512), use octadecyl silane bonded silica as filler [Welch Ultimate AQ-C18 (4.6mm ⁇ 250mm, 5 ⁇ m) or equivalent chromatogram Column]; Using 0.1% phosphoric acid solution as mobile phase A and methanol as mobile phase B, perform linear gradient elution according to the following table; flow rate is 1.0 ml per minute; column temperature is 35°C; detection wavelength is 254 nm. Accurately measure 20 ⁇ l of the test solution, inject it into the liquid chromatograph, record the chromatogram, and calculate the content of compound B, compound C, impurity I and impurity II by area normalization.
- the molecular sieve is crushed, it is put into a crucible, placed in a muffle furnace and heated to 400°C ⁇ 10°C for 2 hours, cooled to 100°C ⁇ 10°C for 1 hour, then transferred to a large airtight dry container filled with nitrogen for storage, and cooled More than 3h.
- W/W is expressed as the mass ratio of molecular sieve to compound B; unknown impurities are not listed.
- R 1 Me, about 3.53 mol, calculated as 1 eq
- compound C (2.5mol, counted as 1eq), trifluoromethanesulfonic anhydride (1eq), N,N-diisopropylethylamine (3eq) and 4-dimethylaminopyridine (0.5eq)
- pyridine solution Put into the pyridine solution, carry out the reaction, after the reaction is finished, separate and purify by the silica gel column, obtain compound D.
- compound D (2.5mol, calculated as 1eq), palladium acetate (0.1eq), 1,1'-bis(diphenylphosphine)ferrocene (0.1eq), N-ethyl diiso Propylamine (2eq) and formic acid (2eq) were added to the solvent dioxane and reacted at 40-60°C. After the reaction was completed, compound E was obtained.
- reaction formula add 1.0M sodium hydroxide aqueous solution, stir at room temperature for 1 h, adjust the pH of the hydrochloric acid aqueous solution to 3-4, perform salting and crystallization, and then suction filtration and drying to obtain compound F with a purity of >98%.
- reaction results were detected by HPLC, and the area normalization method was used to calculate the content of products and impurities. The results are shown in the following table.
Abstract
Description
化合物BCompound B | 化合物CCompound C | 杂质IImpurity I | 杂质IIImpurity II |
13.92%13.92% | 17.71%17.71% | 16.43%16.43% | 44.35%44.35% |
Claims (40)
- 一种式C化合物的制备方法,路线如下:A method for preparing a compound of formula C, the route is as follows:其中,化合物B在无水MgX 2、YI和四丁基卤化铵存在的条件下,反应得到化合物C,其中R 1选自C1-C3的烷基,X为卤素,Y为碱金属。 Wherein, compound B is reacted in the presence of anhydrous MgX 2 , YI and tetrabutylammonium halide to obtain compound C, wherein R 1 is selected from C1-C3 alkyl, X is halogen, and Y is alkali metal.
- 如权利要求1所述的制备方法,X选自Cl、Br或I。The preparation method according to claim 1, wherein X is selected from Cl, Br or I.
- 如权利要求2所述的制备方法,X为Cl。The preparation method according to claim 2, wherein X is Cl.
- 如权利要求1所述的制备方法,Y选自Na或K。The preparation method according to claim 1, wherein Y is selected from Na or K.
- 如权利要求4所述的制备方法,Y为K。The preparation method according to claim 4, Y is K.
- 如权利要求1所述的制备方法,四丁基卤化铵选自四丁基氯化铵、四丁基溴化铵或四丁基碘化铵中的一种或两种以上混合物。The preparation method according to claim 1, wherein the tetrabutylammonium halide is selected from one or a mixture of two or more of tetrabutylammonium chloride, tetrabutylammonium bromide or tetrabutylammonium iodide.
- 如权利要求6所述的制备方法,四丁基卤化铵为四丁基碘化铵。The preparation method according to claim 6, wherein the tetrabutylammonium halide is tetrabutylammonium iodide.
- 如权利要求1所述的制备方法,R 1为甲基、乙基、正丙基或异丙基。 The preparation method according to claim 1, wherein R 1 is methyl, ethyl, n-propyl or isopropyl.
- 如权利要求8所述的制备方法,R 1为甲基。 The preparation method according to claim 8, wherein R 1 is a methyl group.
- 如权利要求1所述的制备方法,以摩尔比计,按照化合物B:MgX 2:YI:四丁基卤化铵=1:1~3:0.5~2:0.1~2的量投料进行反应。 The preparation method according to claim 1, wherein the compound B: MgX 2 : YI: tetrabutylammonium halide=1:1~3:0.5~2:0.1~2 are charged and reacted in molar ratio.
- 如权利要求10所述的制备方法,以摩尔比计,按照化合物B:MgX 2:YI:四丁基卤化铵=1:1.5~2:1~2:0.3~1的量投料进行反应。 The preparation method according to claim 10, based on the molar ratio, the compound B: MgX 2 : YI: tetrabutylammonium halide=1:1.5-2:1-2:0.3-1 is charged and reacted.
- 如权利要求11所述的制备方法,以摩尔比计,按照化合物B:MgX 2:YI:四丁基卤化铵=1:1.7:1.6:0.5的量投料进行反应。 The preparation method according to claim 11, based on the molar ratio, the compound B: MgX 2 : YI: tetrabutylammonium halide=1:1.7:1.6:0.5 is charged and reacted.
- 如权利要求1所述的制备方法,反应溶剂为四氢呋喃、二氧六环或乙二醇二甲醚。The preparation method according to claim 1, wherein the reaction solvent is tetrahydrofuran, dioxane or ethylene glycol dimethyl ether.
- 如权利要求13所述的制备方法,反应溶剂为四氢呋喃。The preparation method according to claim 13, wherein the reaction solvent is tetrahydrofuran.
- 如权利要求1所述的制备方法,反应温度为35~75℃。The preparation method according to claim 1, wherein the reaction temperature is 35-75°C.
- 如权利要求15所述的制备方法,反应温度为50~75℃。The preparation method according to claim 15, wherein the reaction temperature is 50-75°C.
- 如权利要求16所述的制备方法,反应温度为50~60℃。The preparation method according to claim 16, wherein the reaction temperature is 50-60°C.
- 如权利要求1所述的制备方法,反应时间为6~48h。The preparation method according to claim 1, wherein the reaction time is 6 to 48 hours.
- 如权利要求18所述的制备方法,反应时间为10~36h。The preparation method according to claim 18, the reaction time is 10 to 36 hours.
- 如权利要求19所述的制备方法,反应时间为12~24h。The preparation method according to claim 19, the reaction time is 12-24h.
- 如权利要求1所述的制备方法,反应过程在控制水的条件下进行。The preparation method according to claim 1, wherein the reaction process is carried out under controlled water conditions.
- 如权利要求21所述的制备方法,反应体系的水分控制在3%以内。The preparation method according to claim 21, wherein the water content of the reaction system is controlled within 3%.
- 如权利要求22所述的制备方法,反应体系的水分控制在1%以内。The preparation method according to claim 22, wherein the water content of the reaction system is controlled within 1%.
- 如权利要求21-23任意一项所述的制备方法,通入氮气和/或加入分子筛方法控制水分。According to the preparation method according to any one of claims 21-23, nitrogen is introduced and/or molecular sieve is added to control moisture.
- 如权利要求24所述的制备方法,加入分子筛的量,以质量计,为化合物B的0.2~1倍。The preparation method according to claim 24, wherein the amount of molecular sieve added is 0.2 to 1 times that of compound B by mass.
- 如权利要求27所述的制备方法,加入分子筛的量,以质量计,为化合物B的0.4~0.6倍。The preparation method according to claim 27, wherein the amount of molecular sieve added is 0.4 to 0.6 times that of compound B by mass.
- 如权利要求28所述的制备方法,加入分子筛的量,以质量计,为化合物B的0.5倍。The preparation method according to claim 28, wherein the amount of molecular sieve added is 0.5 times that of compound B by mass.
- 如权利要求1所述的制备方法,所述MgX 2、YI和四丁基卤化铵采用分批投料的方式加入反应容器。 The preparation method according to claim 1, wherein the MgX 2 , YI and tetrabutylammonium halide are fed into the reaction vessel in batches.
- 如权利要求30所述的制备方法,第一批在反应容器中加入溶剂、化合物B和任选的分子筛;第二批至最后一批投入预分装的MgX 2、YI和四丁基卤化铵的混合物。 The preparation method according to claim 30, the solvent, compound B and optional molecular sieve are added into the reaction vessel in the first batch; the pre-packed MgX 2 , YI and tetrabutylammonium halide are put into the second to the last batch mixture.
- 如权利要求30或31所述的制备方法,分批投料的批次为3~10批。The preparation method according to claim 30 or 31, wherein the batches of batch feeding are 3-10 batches.
- 如权利要求30或31所述的制备方法,分批投料的批次为4~8批。The preparation method according to claim 30 or 31, wherein the batches of batch feeding are 4-8 batches.
- 如权利要求30或31所述的制备方法,分批投料的批次为4~7批。The preparation method according to claim 30 or 31, the batches of batch feeding are 4-7 batches.
- 如权利要求30或31所述的制备方法,分批投料的批次为6批。The preparation method according to claim 30 or 31, wherein the batch of batch feeding is 6 batches.
- 一种化合物C的制备方法,路线如下:A preparation method of compound C, the route is as follows:其中,化合物B在MgCl 2、KI、TBAI和分子筛存在的条件下,加热反应,得到化合物C,其中,以摩尔比计,按照化合物B:MgCl 2:KI:TBAI=1:1.7:1.6:0.5的量投料进行反应;以质量比计,分子筛为化合物B的0.5倍;反应温度为50~60℃;反应时间为11~15h;该反应采用分批投料的方式进行。 Wherein, compound B is heated and reacted in the presence of MgCl 2 , KI, TBAI and molecular sieves to obtain compound C, wherein, in molar ratio, according to compound B: MgCl 2 : KI: TBAI=1:1.7:1.6:0.5 The reaction is carried out in the amount of feeding; in terms of mass ratio, the molecular sieve is 0.5 times that of compound B; the reaction temperature is 50-60°C; the reaction time is 11-15h; the reaction is carried out by batch feeding.
- 一种式D化合物的制备方法,先采用权利要求1-35任一项所述的制备方法或权利要求36所述的制备方法制得化合物C,再按照如下反应路线进一步得到化合物D:A method for preparing a compound of formula D, firstly using the preparation method of any one of claims 1-35 or the preparation method of claim 36 to obtain compound C, and then further obtain compound D according to the following reaction route:
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910466305.4 | 2019-05-31 | ||
CN201910466305.4A CN112010913B (en) | 2019-05-31 | 2019-05-31 | Preparation method of 4-deoxy daunorubicin |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020237836A1 true WO2020237836A1 (en) | 2020-12-03 |
Family
ID=73500549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/100198 WO2020237836A1 (en) | 2019-05-31 | 2019-08-12 | Preparation method for 4-idarubicin hydrochloride |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112010913B (en) |
WO (1) | WO2020237836A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115785168B (en) * | 2022-08-22 | 2023-11-07 | 浙江亚瑟医药有限公司 | Method for preparing 4-demethoxydaunorubicin hydrochloride |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010028667A1 (en) * | 2008-09-11 | 2010-03-18 | W.C. Heraeus Gmbh | Genetically modified strains for biotransformations in anthracycline production |
US8846882B2 (en) * | 2011-04-29 | 2014-09-30 | Synbias Pharma Ag | Method of producing 4-demethoxydaunorubicin |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1262565B (en) * | 1993-09-30 | 1996-07-04 | Menarini Farma Ind | ANTHRACYCLINE DISACCARIDES, THEIR PREPARATION PROCESSES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
EP2233465B1 (en) * | 2008-01-10 | 2017-06-28 | Shanghai Institute of Pharmaceutical Industry | Preparation method of rivastigmine, its intermediates and preparation method of the intermediates |
CN101993446B (en) * | 2009-08-13 | 2012-11-28 | 中国科学院上海药物研究所 | Novel benzanthracene cyclic compounds and preparation method and use thereof |
CN102336704B (en) * | 2011-10-19 | 2013-04-17 | 丁克 | Method for preparing Roflumilast |
CN108003118A (en) * | 2017-12-27 | 2018-05-08 | 张家口市格瑞高新技术有限公司 | A kind of posaconazole intermediate 1-(4- hydroxy phenyls)-4-(4- aminophenyls)The preparation process of-piperazine |
CN108658730A (en) * | 2018-05-11 | 2018-10-16 | 常州大学 | A kind of preparation method of p-fluorophenol |
-
2019
- 2019-05-31 CN CN201910466305.4A patent/CN112010913B/en active Active
- 2019-08-12 WO PCT/CN2019/100198 patent/WO2020237836A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010028667A1 (en) * | 2008-09-11 | 2010-03-18 | W.C. Heraeus Gmbh | Genetically modified strains for biotransformations in anthracycline production |
US8846882B2 (en) * | 2011-04-29 | 2014-09-30 | Synbias Pharma Ag | Method of producing 4-demethoxydaunorubicin |
Non-Patent Citations (1)
Title |
---|
PU, GANG ET AL.: "Semisynthesis of Idarubicin", CHINESE JOURNAL OF ANTIBIOTICS, no. 03, 30 April 2006 (2006-04-30), DOI: 8980301 * |
Also Published As
Publication number | Publication date |
---|---|
CN112010913A (en) | 2020-12-01 |
CN112010913B (en) | 2022-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017084401A1 (en) | Sugammadex preparation and purification method | |
EP2794633A2 (en) | Synthesis of abiraterone and related compounds | |
CN104447934B (en) | A kind of purification process of Abiraterone acetate | |
TW201704234A (en) | Crystals of azabicyclic compound | |
CN108047265A (en) | A kind of everolimus intermediate prepares purification process | |
CN107325082B (en) | Preparation method of high-purity afatinib | |
WO2020237836A1 (en) | Preparation method for 4-idarubicin hydrochloride | |
US20140011992A1 (en) | Synthesis of abiraterone and related compounds | |
CN109134500A (en) | A kind of 1/2 water cefradine compound | |
CN109096306A (en) | A kind of 1/2 water Cefazolin sodium compound | |
CN111253392B (en) | Method for preparing apixaban | |
JPH03240794A (en) | Crystal of 2'-deoxy-2'-methylidenecytidine dihydrate | |
CN109678701B (en) | Preparation method of vilanterol intermediate | |
CN105753732A (en) | Crystal form of AHU377 as well as preparation method and application thereof | |
WO2016124125A1 (en) | New crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride | |
CN113603813A (en) | Impurity of diphenyl phosphate derivative as sugammadex sodium intermediate and preparation method thereof | |
CN112724110A (en) | Synthesis method of VEGFR inhibitor furoquintinib and benzofuran intermediate thereof | |
CN110759848A (en) | Ethanesulfonic acid nintedanib impurity as well as preparation method and application thereof | |
CN112898277B (en) | Preparation method of afatinib intermediate | |
CN114163380B (en) | Alvacpam intermediate and preparation method and application thereof | |
CN111574448B (en) | Preparation method of phenyl tetrahydroisoquinoline | |
CN115785048B (en) | GL-V9 crystal form and preparation method thereof | |
CN109293613B (en) | Epidaunorubicin intermediate compound | |
CN114057684B (en) | Synthesis method of tiotropium bromide intermediate methyl bis (2-dithienyl) glycolate | |
WO2018233273A1 (en) | Industrial preparation method for high-purity dicycloplatin needle-like crystal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19930222 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19930222 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19930222 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 27/06/2022) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19930222 Country of ref document: EP Kind code of ref document: A1 |